HPAPIS AND CYTOTOXIC DRUGS MANUFACTURING MARKET ANALYSIS

HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin (Chemical-based HPAPIs and Biologic-based HPAPIs), by Manufacturing Location (In-house Manufacturing and Outsourcing), by Drug Type (Novel HPAPIs and Generic HPAPIs), by Type of Pharmacological Molecule (Small Molecules and Biologics), by Application (Oncology, Respiratory, Ophthalmic Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : May 2022
Code : CMI1312
Pages :309
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global HPAPIs and Cytotoxic Drugs Manufacturing Market – Regional Analysis

On the basis of region, global HPAPIs and cytotoxic drugs manufacturing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America HPAPIs and cytotoxic drugs manufacturing market is expected to hold a dominant position during the forecast period, owing to the increasing number of product approvals in the region. For instance, in 2019, Pfizer Inc. received approval from the U.S. Food and Drug Administration (FDA) for RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan (rituximab) which is indicated for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Furthermore, Europe is also estimated to witness significant growth in the global HPAPIs and cytotoxic drugs manufacturing market, owing to expansion of the HPAPI manufacturing facility in the region. For instance, in May 2021, Novasep, a leading provider of services and solutions to the life sciences industry, announced that its manufacturing capabilities for Highly Potent Active Pharmaceutical Ingredients (HPAPIs) had been expanded at its Le Mans (72 – France) site. Novasep's position as a leading CDMO for the manufacturing of innovative and tailored medicines to treat cancer is strengthened by this new step.

Figure 2: Global HPAPIs and Cytotoxic Drugs Manufacturing Market (US$ Bn), by Region, 2022